Identification of Non-competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-opioid Therapeutic Strategy for Neuropathic Pain
- 15 April 2026
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10278-10314
Abstract
Glycine transporter 2 (GlyT2) regulates extracellular glycine in the central nervous system (CNS) and is a promising target for restoring inhibitory neurotransmission in chronic pain. Although GlyT2 inhibitors show analgesic efficacy in rodent neuropathic pain models, the prototypical inhibitor ORG25543 (1) is limited by poor pharmacological properties, including slow dissociation kinetics and neuromotor toxicity at therapeutic doses, recapitulating the phenotype of homozygous GlyT2 knockout (GlyT2–/–) mice. To address these challenges, we developed a series of second-generation, conformationally restricted indoline analogues that act as noncompetitive and reversible GlyT2 inhibitors with varied potency and recovery kinetics. Among them, RPI-GLYT2-82 produced effective analgesia in murine neuropathic pain models without inducing excitatory neuromotor side effects observed with ORG25543. Collectively, these findings underscore the translational potential of reversible GlyT2 inhibitors as safe, nonopioid therapeutics for the management of neuropathic pain and provide a foundation for continued optimization of this chemotype toward preclinical candidate selection.Keywords
All Related Versions
Funding Information
- Novo Nordisk Fonden (NNF23OC0087107)
- National Institute on Drug Abuse (NIH R01DA048879)
- Lundbeck Foundation (R368-2021-522)
This publication has 41 references indexed in Scilit:
- Estimates of Pain Prevalence and Severity in Adults: United States, 2012The Journal of Pain, 2015
- Analgesic effect of GT-0198, a structurally novel glycine transporter 2 inhibitor, in a mouse model of neuropathic painJournal of Pharmacological Sciences, 2015
- A series of case studies: practical methodology for identifying antinociceptive multi-target drugsDrug Discovery Today, 2012
- Glycine Transporter Type 2 (GlyT2) Inhibitor Ameliorates Bladder Overactivity and Nociceptive Behavior in RatsEuropean Urology, 2012
- Development of synaptic inhibition in glycine transporter 2 deficient miceMolecular and Cellular Neuroscience, 2010
- Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic painPharmacology & Therapeutics, 2009
- Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic painNeuroscience Letters, 2008
- The glycinergic control of spinal pain processingCellular and Molecular Life Sciences, 2005
- 5,5-Diaryl-2-amino-4-pentenoates as novel, potent, and selective glycine transporter type-2 reuptake inhibitorsBioorganic & Medicinal Chemistry Letters, 2001
- Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common geneNeuron, 1993